Journal of controlled release : official journal of the Controlled Release SocietyJul 13, 2026

Design and early testing of non-viral, non-fat-based nanoparticles for RNA treatments

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 14, 2026

Abstract

RNA therapeutics face limitations in clinical application due to factors like inefficient delivery and long-term safety concerns.

Non-viral and non-lipid RNA nanocarriers are examined for their potential in overcoming delivery challenges.
Different RNA delivery methods, such as polymeric nanoparticles and virus-like particles, are analyzed for their effectiveness in targeting specific tissues.
Cross-platform evaluations consider factors like RNA release efficiency and immune interactions to assess carrier performance.
Carrier design significantly affects how well RNA can be distributed within the body and its subsequent therapeutic effectiveness.
Clinically validated lipid nanoparticle formulations set standards for assessing the performance of alternative non-lipid delivery systems.

Simplified

RNA therapeutics have emerged as versatile platforms for gene modulation and protein expression in vaccination, oncology, genetic disorders, and inflammatory diseases. However, their broader clinical application remains limited by inefficient delivery, insufficient tissue specificity, inadequate intracellular bioavailability, and long-term safety concerns. This review examines non-viral and non-lipid RNA nanocarriers from mechanistic and translational perspectives. We outline the cargo-specific delivery requirements of various RNA modalities and analyze polymeric nanoparticles, inorganic nanomaterials, peptide- and protein-based carriers, and virus-like particles as distinct strategies to overcome extracellular, tissue-level, cellular, and intracellular barriers. Cross-platform trade-offs are evaluated based on RNA association and release, cargo compatibility, administration route, biodegradability, immune interactions, and manufacturability. We further discuss how carrier architecture influences biodistribution, intracellular RNA activity, and therapeutic efficacy across major disease areas. Clinically validated lipid nanoparticle (LNP) formulations serve as translational benchmarks, while non-lipid systems are evaluated based on productive delivery, release efficiency, repeat-dose compatibility, long-term material fate, scalability, and regulatory feasibility. By integrating cargo requirements, barrier resolution, intracellular trafficking, and translational benchmarking, this review highlights non-viral and non-lipid nanocarriers as complementary platforms for context-specific RNA therapy.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

No commercial or financial ties reported.

PubMed

Design and early testing of non-viral, non-fat-based nanoparticles for RNA treatments

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief